Icad INC 8-K filings

RadNet, Inc.'s wholly-owned subsidiary, DeepHealth, has completed the acquisition of iCAD, Inc., integrating iCAD's AI-powered breast health solutions to enhance DeepHealth's market position and accelerate AI adoption globally.

iCAD, Inc. stockholders have approved the Agreement and Plan of Merger with RadNet, Inc., paving the way for the acquisition to close on July 17, 2025.

iCAD's Board of Directors approved an amendment to the exercise provisions of certain stock options in connection with the pending merger with RadNet, Inc.

iCAD, Inc. announced its Q1 2025 financial results, highlighting a flat revenue year-over-year but improved gross margins and progress in its transition to cloud-based solutions, while also noting a pending acquisition by RadNet.

RadNet will acquire iCAD in an all-stock transaction valued at approximately $103 million, combining their AI-powered breast cancer detection and workflow solutions.

iCAD, Inc. announces its Q4 and full-year 2024 financial results, highlighting a 14% increase in total revenues and an 11% rise in Annual Recurring Revenue (ARR) as it transitions to a SaaS-based model.

iCAD reports preliminary unaudited Q4 2024 revenue between $5.1 and $5.3 million and an 11% year-over-year increase in Total Annual Recurring Revenue.

iCAD's third quarter results show a 10% year-over-year increase in annual recurring revenue, fueled by strong cloud adoption and the launch of an enhanced AI-powered breast cancer detection solution.

iCAD, Inc. announced a 21% increase in total revenue for the second quarter of 2024, driven by strong performance in its AI-powered breast health solutions.

iCAD, Inc. held its 2024 annual meeting where stockholders approved the 2024 Omnibus Equity Incentive Plan and elected six directors to the board.

iCAD, Inc. announced a 14% increase in total revenue and improved profitability for the first quarter of 2024, driven by its AI-powered breast health solutions.

iCAD announced its fiscal fourth quarter and full-year 2023 financial results, highlighting a 15% increase in annual recurring revenue and significant improvements in operating cash flow.

iCAD, Inc. has appointed Dr. Hedvig Hricak to its Board of Directors, effective immediately, and granted her stock options.

iCAD, Inc. has appointed Michael John Doyle to its Board of Directors, effective immediately, and granted him an equity incentive in the form of an option to purchase 40,000 shares.